Pasar al contenido principal

FACTORES ASOCIADOS A LOS RECEPTORES DE TNF (TRAF)-3 Y MOTIVO TRIPARTITO (TRIM)-37: NUEVAS FUNCIONES EN EL CONTROL DE LA INMUNIDAD INNATA Y ADAPTATIVA EN RESPUESTA A PATOGENOS.

PID2019-110405RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR

  • Compte, Marta
  • Harwood, Seandean L.
  • Martínez-Torrecuadrada, Jorge
  • Pérez-Chacón, Gema
  • González-García, Patricia
  • Tapia-Galisteo, Antonio
  • Bergen en Henegouwen, Paul M. P. Van
  • Sánchez Muñoz, Aranzazu
  • Fabregat, Isabel
  • Sanz, Laura
  • Zapata, Juan M.
  • Álvarez-Vallina, Luis
Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been hampered by dose-limiting liver toxicity. We have previously developed an EGFR-targeted 4-1BBagonistic trimerbody (1D8N/CEGa1) that induces potent anti-tumor immunity without systemic toxicity, in immunocompetent mice bearing murine colorectal carcinoma cells expressing human EGFR. Here, we study the impact of human EGFR expression on mouse liver in the toxicity profile of 1D8N/CEGa1. Systemic administration of IgG-based anti-4-1BB agonist resulted in nonspecific immune stimulation and hepatotoxicity in a liver-specific human EGFR-transgenic immunocompetent mouse, whereas in 1D8N/CEGa1-treated mice no such immune-related adverse effects were observed. Collectively, these data support the role of FcgR interactions in the major offtumor toxicities associated with IgG-based 4-1BB agonists and further validate the safety profile of EGFR-targeted Fc-less 4-1BB-agonistic trimerbodies in systemic cancer immunotherapy protocols.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Editorial: Mouse Models of B Cell Malignancies

  • Pérez-Chacón, Gema
  • Vincent-Fabert, Christelle
  • Zapata, Juan M.
© 2021 Perez-Chacon, Vincent-Fabert and Zapata., B cell malignancies represent a vast group of different entities arising from the multiple differentiation stages of B cells. In humans, there is a large variety of B cell malignancies, most of which have counterparts in mice. Prognosis and treatment for these malignancies would be largely dependent on their type, stage and grade., GP-C and JMZ were supported by a grant from the Agencia Estatal de Investigacion (PID2019-110405RB-I00/AEI/10.13039/ 501100011033). CV-F was supported by the France Lymphome Espoir association of patients and the Ligue contre le cancer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Traf2DNxBCL2-tg mouse model of chronic lymphocytic leukemia/small lymphocytic lymphoma recapitulates the biased IGHV gene usage, stereotypy, and antigen-specific HCDR3 selection of its human counterpart

  • Pérez-Chacón, Gema
  • Zapata, Juan M.
© 2021 Perez-Chacon and Zapata., Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) is a heterogeneous disease consisting of at least two separate subtypes, based on the mutation status of the immunoglobulin heavy chain variable gene (IGHV) sequence. Exposure to antigens seems to play a role in malignant transformation and in the selection and expansion of more aggressive CLL clones. Furthermore, a biased usage of particular IGHV gene subgroups and the existence of stereotyped B-cell receptors (BCRs) are distinctive characteristics of human CLL. We have previously described that Traf2DN/BCL2 double-transgenic (tg, +/+) mice develop CLL/SLL with high incidence with aging. In this model, TNF-Receptor Associated Factor (TRAF)-2 deficiency cooperates with B cell lymphoma (BCL)-2 in promoting CLL/SLL in mice by specifically enforcing marginal zone (MZ) B cell differentiation and rendering B cells independent of BAFF for survival. In this report, we have performed the sequencing of the IGHV-D-J rearrangements of B cell clones from the Traf2DN/BCL2-tg+/+ mice with CLL/SLL. The results indicate that these mice develop oligoclonal and monoclonal B cell expansions. Allotransplantation of the oligoclonal populations into immunodeficient mice resulted in the preferential expansion of one of the parental clones. The analysis of the IGHV sequences indicated that 15% were mutated (M) and 85% unmutated (UM). Furthermore, while the Traf2DN/BCL2-tg-/- (wild-type), -/+ (BCL2 single-tg) and +/- (Traf2DNDN single-tg) littermates showed the expression of various IGHV gene subgroups, the CLL/SLL expanded clones from the Traf2DN/BCL2-tg+/+ (double-transgenic) mice showed a more restricted IGHV gene subgroup usage and an overrepresentation of particular IGHV genes. In addition, the HCDR3-encoded protein sequence indicates the existence of stereotyped immunoglobulin (Ig) in the BCRs and strong similarities with BCR recognizing autoantigens and pathogen-associated antigens. Altogether, these results highlight the remarkable similarities between the CLL/SLL developed by the Traf2DN/BCL2-tg+/+ mice and its human counterpart., This work was supported by grants from the Agencia Estatal de Investigacion (PID2019-110405RB-I00/AEI/10.13039/501100011033) and from the Instituto de Salud Carlos III (PI16/000895). We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI). The cost of this publication was paid in part by FEDER funds.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

  • González-Vaz, Javier
  • Azpilikueta, Arantza
  • Ochoa, Maria Carmen
  • Olivera, Irene
  • Gomis, Gabriel
  • Cirella, Asunta
  • Luri-Rey, Carlos
  • Álvarez, Maite
  • Perez-Gracia, Jose L.
  • Ciordia, Sergio
  • Eguren-Santamaria, Iñaki
  • Alexandru, Raluca
  • Berraondo, Pedro
  • Andrea, Carlos de
  • Teijeira, Alvaro
  • Corrales, Fernando J.
  • Zapata, Juan M.
  • Melero, Ignacio
CD137 (4-1BB) is a member of the TNFR family that mediates potent T cell costimulatory signals upon ligation by CD137L or agonist monoclonal antibodies (mAbs). CD137 agonists attain immunotherapeutic antitumor effects in cancer mouse models, and multiple agents of this kind are undergoing clinical trials. We show that cIAP1 and cIAP2 are physically associated with the CD137 signaling complex. Moreover, cIAPs are required for CD137 signaling toward the NF-κB and MAPK pathways and for costimulation of human and mouse T lymphocytes. Functional evidence was substantiated with SMAC mimetics that trigger cIAP degradation and by transfecting cIAP dominant-negative variants. Antitumor effects of agonist anti-CD137 mAbs are critically dependent on the integrity of cIAPs in cancer mouse models, and cIAPs are also required for signaling from CARs encompassing CD137’s cytoplasmic tail., I.M. has been granted with PID2020-112892RB funded by MICIN/AEI/10.13039/501100011033 and SAF2017-83267-C2-1-R funded by MICIN/AEI/10.13039/501100011033/ and by FEDER “Una manera de hacer Europa,” (HR21-00083) the Fundación La Caixa, “MINCITH. Metabolic requirements for immune INfiltration in effective Cancer ImmunoTHerapy” “AYUDAS FUNDACIÓN BBVA A EQUIPOS DE INVESTIGACIÓN CIENTÍFICA 2019” Fundación BBVA, the Instituto de Salud Carlos III (PI20/00002 and PI19/01128), cofinanced by the Fondos FEDER “A way to make Europe” and Joint Translational Call for Proposals 2015 (JTC 2015), TRANSCAN456 2 (code TRS-2016-00000371), and the Gobierno de Navarra Proyecto LINTERNA (reference 0011-1411-2020-000075). Funding was also received from B. J. Baselga (Fundación FERO) and the T2-EVOLVE project from the EU. I.M. and M.A. receive grant funding from Pharmamar and Highlight Therapeutics. M.A. is supported by AECC (INVES1904ALVA). J.M.Z. has been granted with PID2019-110405RB-I00 funded by MICIN/AEI/10.13039/501100011033 and with P2022/BMD-7225 funded by Consortium in Biomedicine of Comunidad de Madrid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR

  • Compte, Marta
  • Harwood, Seandean L.
  • Martínez-Torrecuadrada, Jorge
  • Pérez-Chacón, Gema
  • González-García, Patricia
  • Tapia-Galisteo, Antonio
  • Bergen en Henegouwen, Paul M. P. Van
  • Sánchez, Aránzazu
  • Fabregat, Isabel
  • Sanz, Laura
  • Zapata, Juan M.
  • Álvarez-Vallina, Luis
Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are among the most effective immunotherapeutic agents across pre-clinical cancer models. However, clinical development of full-length 4-1BB agonistic mAbs, has been hampered by dose-limiting liver toxicity. We have previously developed an EGFR-targeted 4-1BB-agonistic trimerbody (1D8N/CEGa1) that induces potent anti-tumor immunity without systemic toxicity, in immunocompetent mice bearing murine colorectal carcinoma cells expressing human EGFR. Here, we study the impact of human EGFR expression on mouse liver in the toxicity profile of 1D8N/CEGa1. Systemic administration of IgG-based anti-4-1BB agonist resulted in nonspecific immune stimulation and hepatotoxicity in a liver-specific human EGFR-transgenic immunocompetent mouse, whereas in 1D8N/CEGa1-treated mice no such immune-related adverse effects were observed. Collectively, these data support the role of FcγR interactions in the major off-tumor toxicities associated with IgG-based 4-1BB agonists and further validate the safety profile of EGFR-targeted Fc-less 4-1BB-agonistic trimerbodies in systemic cancer immunotherapy protocols., This study was supported by grants from the European Union [IACT Project (602262)], the Spanish Ministry of Science and Innovation; the Spanish Ministry of Economy and Competitiveness (SAF2017-89437-P, PID2019-110405RB-100, RTC-2016-5118-1, RTC-2017-5944-1), partially supported by the European Regional Development Fund; the Carlos III Health Institute (PI16/00357), co-founded by the Plan Nacional de Investigación and the European Union; the CRIS Cancer Foundation (FCRIS-IFI-2018), and the Spanish Association Against Cancer (AECC, 19084)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Indole-3-carbinol is an inhibitor of KV1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells

  • Baena-Nuevo, M.
  • Vera-Zambrano, Alba
  • Martínez-Laperche, Carolina
  • Buño, Ismael
  • Muñoz-Calleja, Cecilia
  • Valenzuela, Carmen
  • Zapata, Juan M.
  • Pérez-Chacón, Gema
Potassium voltage-gated channels are attractive drug targets for cancer treatment. In this report, we show that KV1.3 current amplitude is greater in CLL cells from refractory patients compared to CLL cells from untreated patients, further supporting a role for Kv1.3 channel as a target for refractory CLL disease. Indole-3 carbinol (I3C) is a clinically tested natural product found in edible Brassica plants. Here we show that I3C inhibits KV1.3 currents in transfected HEK293 (43.9 ± 7.6 %; 50 μM I3C), Burkitt's lymphoma BL60.2 (52.2 ± 5.2 %; 10 μM) and chronic lymphocytic leukemia (CLL) (57.7 % ± 5.2; 10 μM) cells. I3C inhibition was concentration-dependent in HEK293 (IC50 = 54 μM; nH = 3.2), BL60.2 (IC50 = 1.06 μM; nH = 0.53) and CLL (IC50 = 5.2 μM; nH = 0.95) cells, and the effect on KV1.3 was produced in a voltage-, time- and use-dependent manner, consistent with an open state blockade mechanism. I3C also inhibited KV11.1 currents, but failed to inhibit other KV channels and Kca3.1. Interestingly I3C did not induce mitochondrial depolarization of CLL cells, suggesting that I3C only targets plasma, but not mitochondria, Kv1.3 channels. I3C and derivatives 6-methyl-I3C and 3,3′-diindolylmethane, but no other indoles, that we previously showed induced apoptosis in Burkitt's and CLL cells, also efficiently inhibited KV1.3 currents. However, I3C-mediated KV1.3 currents inhibition was observed in CLL cells irrespective of their sensitivity to I3C-induced cell death, thus indicating that plasma membrane KV1.3 inhibition is not sufficient to induce CLL cell death., This study was supported by projects PID2019-110405RB-I00 and PID2022-136909OB-I00 (to JMZ), PID2019-104366RB-C21 and PID2022-137214OB-C21 (to CV), all funded by MCIN/AEI/10.13039/501100011033 and ERDF, EU. This study was also supported by Grant CB/11/00222 funded by Instituto de Salud Carlos III CIBERCV (to CV) and by 2023AEP049 funded by CSIC (to CV). It was also supported by S2022/BMD-7223 (to CV) and P2022/BMD-7225 (to JMZ) funded by Consortium in Biomedicine of Comunidad de Madrid., Peer reviewed